*免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 12月15日新股申购 (共1) | | 健信超导(科创板, 688 | | --- | --- | | 申购代码 | 787805 F | | 发行价格 | 18.58元 顶格 | | 总市值 | 23.37亿 | | 发行市盈率 | 61.97 行业 | | 同业可比公司 | 联影医疗 同业公司 动态市监率 | | | 奕瑞科技 | | | 康众医疗 | | | 2025上半年: | | 主营构成 | 超导产品: 73.17% | | | 永磁产品: 26.83% | | | 1、公司主要从事医用磁共振成像 (MRI) 设备核心 、永磁体和梯度线圈等，是全球最大的医用 MRI | | | MRI 设备超导磁体产品以 4.2% 的市占率位居全球 | | 业务及亮点 | 2、公司自 2015 年起在零挥发超导磁体特别是 1. | | --- | --- | | | 欧美、日本厂商长期以来的垄断,为国内最早规4 | | | 3、公司掌握下一代无液氦超导磁体研发生产核心 | | | 超导磁体及 1.5T大孔径无液氦超导磁体。 | | ...

12月5日，宁波健信超导科技股份有限公司（股票简称：健信超导，股票代码：688805）正式披露招股意向书等公告，将在上交所科创板挂牌上市。健信超 导首次公开发行股票不超过4，192.00万股，不低于发行后总股本的25%，发行后总股本不超过16，768.00万股，保荐机构为广发证券。 健信超导初步询价日为12月10日，网上路演日为12月12日，网上、网下申购日为12月15日，网上、网下缴款日为12月17日。本次IPO募集资金将投向年产 600套无液氦超导磁体项目、年产600套高场强医用超导磁体技改项目和新型超导磁体研发项目。 健信超导持续进行研发投入，截至2025年6月30日，拥有授权专利共计85项，其中发明专利45项。公司分别于2023年入选国家专精特新"小巨人"企业、于 2024年入选国家专精特新重点"小巨人"企业。公司设有浙江省高新技术企业研究开发中心、浙江省博士后工作站、院士工作站，已完成宁波市科技创新2025 重大专项"无液氦超导磁体的研发"项目，参与完成工信部医疗器械材料生产应用示范平台项目并具体负责"无液氦超导磁体生产应用示范线、无液氦超导磁 体测试评价和考核验证能力"，报告期内参与科技部国家重点 ...

Group 1 - The core mission of the company is to make MRI technology accessible for everyday medical examinations through independent research and continuous innovation [1] - The company has established close partnerships with well-known MRI equipment manufacturers such as Fujifilm Holdings Corporation and Beijing Wandong Medical Technology Co., Ltd [1] - From 2022 to the first half of 2025, the company reported revenue of 359 million, 451 million, 425 million, and 252 million CNY, with net profits of 34.63 million, 48.73 million, 55.78 million, and 31.92 million CNY respectively, indicating an overall upward trend in revenue [1] Group 2 - The funds raised will be invested in projects including the annual production of 600 sets of helium-free superconducting magnets and the technological transformation of high-field medical superconducting magnets [2] - The company has successfully developed the world's first 1.5T helium-free superconducting magnet, showcasing its core technology in the next generation of superconducting magnets [2] - The company aims to enhance its competitive edge in products and technology, contributing to the domestic substitution of high-end medical equipment and creating long-term value for investors [2]

Core Points - The Shanghai Stock Exchange's Listing Review Committee is scheduled to hold its 43rd meeting on October 21, 2025, to review the initial public offering (IPO) of Ningbo Jianxin Superconducting Technology Co., Ltd. (referred to as "Jianxin Superconducting") [1] - Jianxin Superconducting plans to list on the Sci-Tech Innovation Board and aims to raise CNY 77.5 million, which will be allocated to projects including the annual production of 600 sets of liquid helium-free superconducting magnets, the annual production of 600 sets of high-field medical superconducting magnets, and the research and development of new superconducting magnets [1] Company Ownership Structure - As of the signing date of the prospectus, Xu Jianyi directly holds 41.51% of the company's shares, making him the controlling shareholder. Xu Jianyi, Xu Hui, and Xu Dianbo hold 41.51%, 4.36%, and 4.36% of the shares, respectively. Xu Hui controls an additional 4.84% of voting rights through Kaifang Investment and Qiyi Investment, resulting in a total of 59.92% voting rights controlled by the three individuals [1] - Xu Jianyi is the father of Xu Hui and Xu Dianbo, who are siblings. The three have signed a "Joint Action Agreement" on October 18, 2019, establishing them as the actual controllers of the company [1] Sponsorship Information - The sponsor for Jianxin Superconducting's IPO is GF Securities Co., Ltd., with representatives Zhou Yin and Wang Zhen serving as the sponsoring representatives [1]